D.B. Root & Company’s BioLineRX BLRX Stock Holding History

D.B. Root & Company’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-33	Closed	-$7K	–	193
2019 Q2	$7K	Hold	33	–	–	﹤0.01%	195
2019 Q1	$9K	Hold	33	–	–	﹤0.01%	205
2018 Q4	$9K	Hold	33	–	–	﹤0.01%	189
2018 Q3	$21K	Buy	+33	New	+$18.2K	0.01%	208

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

D.B. Root & Company's BLRX Position: Q3 2019 in Review

D.B. Root & Company sold out of BioLineRX (BLRX) in Q3 2019, closing a stake of 33 shares — an estimated $7K sold.

D.B. Root & Company first reported a position in BLRX in Q3 2018 and held it in 4 quarters. The position peaked at $21K in Q3 2018. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2019.

D.B. Root & Company reported no remaining BioLineRX position as of Q3 2019 after selling out during the quarter.
D.B. Root & Company sold 33 BioLineRX shares in Q3 2019, an estimated $7K.
D.B. Root & Company first reported a position in BioLineRX in Q3 2018 and held it in 4 quarters.
D.B. Root & Company's BioLineRX position peaked at $21K in Q3 2018.
15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2019.

Based on D.B. Root & Company's 13F filing for Q3 2019, filed 29 Oct 2019.